Published in Klin Wochenschr on October 01, 1978
Specific suppression of the antibody response by antibodies to receptors. Proc Natl Acad Sci U S A (1972) 3.02
Specific inhibition of plaque formation to phosphorylcholine by antibody against antibody. Science (1972) 2.73
[Virus proteins. IV. Constitution of the coat protein of the fd phage]. Hoppe Seylers Z Physiol Chem (1969) 2.56
Cyclosporin A-binding protein (cyclophilin) of Neurospora crassa. One gene codes for both the cytosolic and mitochondrial forms. J Biol Chem (1988) 2.43
Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction (2003) 2.06
Regulation of immune response by autogenous antibody against receptor. Proc Natl Acad Sci U S A (1974) 2.05
[Fever of uncertain origin]. Internist (Berl) (1994) 2.02
Incidence and frequency or complications and management of Meckel's diverticulum. Surg Gynecol Obstet (1989) 1.98
Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans. Proc Natl Acad Sci U S A (1991) 1.97
Specific suppression of immune responses. Science (1973) 1.67
Macroglobulin structure: homology of mu and gamma heavy chains of human immunoglobulins. Science (1969) 1.64
Neonatal tolerance induced by antibody against antigen-specific receptor. Science (1974) 1.61
CD14(++)CD16+ monocytes but not total monocyte numbers predict cardiovascular events in dialysis patients. Kidney Int (2007) 1.58
[Use of drugs in residents of homes for the elderly and nursing homes in comparison with patients in ambulatory care or without need of care]. Dtsch Med Wochenschr (2002) 1.54
Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation (2001) 1.54
Antihypertensive effect of N-amidino-2-(2,6-dichlorophenyl) acetamide hydrochloride. A double-blind cross-over trial versus clonidine. Int J Clin Pharmacol Biopharm (1978) 1.50
Evaluation of latent tuberculosis infection in patients with inflammatory arthropathies before treatment with TNF-alpha blocking drugs using a novel flow-cytometric interferon-gamma release assay. Rheumatology (Oxford) (2008) 1.49
The response to phosphorylcholine: dissecting an immune response. Transplant Rev (1975) 1.49
Two major groups of neutralizing anti-gp120 antibodies exist in HIV-infected individuals. Evidence for epitope diversity around the CD4 attachment site. J Immunol (1992) 1.47
Molecular aspects of T- and B-cell function in uremia. Kidney Int Suppl (2001) 1.44
Suppression by autogenous complementary idiotypes: the priority of the first response. J Exp Med (1976) 1.43
A human flora-associated rat model of the breast-fed infant gut. J Pediatr Gastroenterol Nutr (2003) 1.43
Epidemiological features of Adamantiades-Behçet's disease in Germany and in Europe. Yonsei Med J (1997) 1.43
Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics. Clin Pharmacokinet (1988) 1.42
Three variable-gene pools common to IgM, IgG and IgA immunoglobulins. Nature (1970) 1.41
Coronary anomaly in Behçet's syndrome. Rheumatol Int (1997) 1.40
Impaired cellular immune function in patients with end-stage renal failure. Nephrol Dial Transplant (1999) 1.40
[Innovation instead of imitation -- news in drug therapy]. Dtsch Med Wochenschr (2005) 1.39
[Fractures of vital teeth under chronic pain therapy with oxycodone]. Dtsch Med Wochenschr (2006) 1.38
[Quality assurance in bariatric surgery in Germany--results of the German multicentre trial 2005 and 2006]. Zentralbl Chir (2008) 1.38
PD-1 expression and IL-2 loss of cytomegalovirus- specific T cells correlates with viremia and reversible functional anergy. Am J Transplant (2008) 1.34
The aldolase-binding site of the human erythrocyte membrane is at the NH2 terminus of band 3. J Biol Chem (1981) 1.31
Preparation and analysis of seven major, topographically defined fragments of band 3, the predominant transmembrane polypeptide of human erythrocyte membranes. Biochemistry (1978) 1.30
Scopolamine model of dementia: electroencephalogram findings and cognitive performance. Eur J Clin Invest (1998) 1.30
[Sterno-costo-clavicular hyperostosis: a hitherto undescribed entity (author's transl)]. Dtsch Med Wochenschr (1975) 1.28
Import of cytochrome c into mitochondria. Cytochrome c heme lyase. Eur J Biochem (1987) 1.28
Interaction of metoprolol, propranolol and atenolol with concurrent administration of cimetidine. Klin Wochenschr (1982) 1.26
Clonal restriction of the immune response to phosphorylcholine. Nature (1974) 1.25
Impaired cellular immune responses in chronic renal failure: evidence for a T cell defect. Kidney Int (1986) 1.23
Interaction of cimetidine with metoprolol, propranolol, or atenolol. Lancet (1981) 1.22
Anti-receptor antibody. II. Induction of long-term unresponsiveness in neonatal mice. J Immunol (1975) 1.19
T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients. Nephrol Dial Transplant (2000) 1.17
Defective expression of B7-2 (CD86) on monocytes of dialysis patients correlates to the uremia-associated immune defect. Kidney Int (2001) 1.17
Sternocostoclavicular hyperostosis: painful swelling of the sternum, clavicles, and upper ribs. Report of two new cases. Ann Intern Med (1977) 1.16
Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens (2009) 1.16
Biomaterial-induced sarcoma: A novel model to study preneoplastic change. Am J Pathol (2000) 1.15
The cloven hoof in legal medicine. Int J Legal Med (2001) 1.15
Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol Dial Transplant (1997) 1.15
Priapism during regular haemodialysis. Lancet (1974) 1.14
Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol (2008) 1.14
Clinical pharmacokinetics of articaine. Clin Pharmacokinet (1997) 1.13
Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int (1995) 1.12
P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharmacol Ther (2000) 1.10
Recognition and management of overweight and obesity in primary care in Germany. Int J Obes Relat Metab Disord (2004) 1.09
Selective blockade of the antigen-receptor-mediated pathway of T cell activation in patients with impaired primary immune responses. J Clin Invest (1987) 1.09
Clonal depletion in neonatal tolerance. Science (1974) 1.08
Immune response to phosphorylcholine. III. Requirement of the Fc portion and equal effectiveness of IgG subclasses in anti-receptor antibody-induced suppression. J Immunol (1977) 1.08
Tetanus immunization and its association to hepatitis B vaccination in patients with chronic renal failure. Am J Kidney Dis (1995) 1.07
B-cell abnormalities in AIDS: stable and clonally-restricted antibody response in HIV-1 infection. Scand J Immunol (1993) 1.06
Idiotypic networks and nature of molecular mimicry: an overview. Methods Enzymol (1989) 1.05
Comparative macrorestriction and RFLP analysis of Mycobacterium avium subsp. avium and Mycobacterium avium subsp. hominissuis isolates from man, pig, and cattle. Vet Microbiol (2006) 1.05
Unmet needs in the diagnosis and treatment of dyslipidemia in the primary care setting in Germany. Atherosclerosis (2006) 1.05
An immunologic network. Contemp Top Immunobiol (1980) 1.04
Immune response to phosphorylcholine. IX. Characterization of hybridoma anti-TEPC15 antibodies. J Immunol (1982) 1.04
Current trends in biocompatibility testing. Proc Inst Mech Eng H (1998) 1.03
Tobacco use among medical students in Europe: results of a multicentre study using the Global Health Professions Student Survey. Public Health (2011) 1.03
Serological evidence for reactivation of EBV infection due to uraemic immunodeficiency. Nephrol Dial Transplant (1997) 1.02
Adolescents' drug use and drug knowledge. Eur J Pediatr (2000) 1.01
Short- and long-term results after thrombolytic treatment of deep venous thrombosis. J Am Coll Cardiol (2000) 1.01
Nitrocellulose-enzyme-linked immunosorbent assay (NC-ELISA) - a sensitive technique for the rapid visual detection of both viral antigens and antibodies. J Virol Methods (1984) 1.00
Proinflammatory CD14+CD16+ monocytes are associated with subclinical atherosclerosis in renal transplant patients. Am J Transplant (2007) 1.00
Subtypes of acute postinfectious glomerulonephritis. Synopsis of clinical and pathological features. Clin Nephrol (1982) 1.00
[Prevalence and pharmacotherapy of diabetes mellitus in primary care]. Dtsch Med Wochenschr (2005) 0.99
Refractory period, sensory conduction velocity and visual evoked potentials before and after haemodialysis. J Neurol Neurosurg Psychiatry (1981) 0.99
Studies on the regulation of enolases and compartmentation of cytosolic enzymes in Saccharomyces cerevisiae. Biochim Biophys Acta (1987) 0.99
In vivo effects of dialysate flow rate on Kt/V in maintenance hemodialysis patients. Am J Kidney Dis (2000) 0.98
Combined MLST and AFLP typing of Bartonella henselae isolated from cats reveals new sequence types and suggests clonal evolution. Vet Microbiol (2010) 0.98
Influence of clinical factors, diet, and drugs on the human upper gastrointestinal glutathione system. Gut (2002) 0.98
Light chain isotypes selectively associate with heavy chain idiotypes in T-dependent and T-independent dextran-specific precursors. Nature (1981) 0.98
DNA repair in Proteus mirabilis. VI. Plasmid (R46-) mediated recovery and UV mutagenesis. Mol Gen Genet (1979) 0.98
T cell activation defect in hemodialysis patients: evidence for a role of the B7/CD28 pathway. Kidney Int (1993) 0.97
The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens Suppl (2001) 0.97
Dose dependent tiracizine disposition in healthy volunteers: serum and urine kinetics and dose related ECG-changes. Eur J Drug Metab Pharmacokinet (1995) 0.97
Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination. Lancet (1989) 0.97
[Clinical pharmacokinetics of Articain after intraoral and intramuscular applications]. SSO Schweiz Monatsschr Zahnheilkd (1983) 0.96
Elimination and haemodynamic effects of nitrendipine in patients with chronic renal failure. Eur J Clin Pharmacol (1989) 0.96
Human monoclonal and polyclonal anti-human immunodeficiency virus-1 antibodies share a common clonotypic specificity. Eur J Immunol (1992) 0.96
Antibody-dependent cell-mediated cytotoxicity. I. Differentiation from antibody-independent cytotoxicity by "normal" IgG. J Immunol (1974) 0.96
Production of proinflammatory and regulatory monokines in hemodialysis patients shown at a single-cell level. J Am Soc Nephrol (1998) 0.96
Natural mouse and human antibodies bind to a peptide derived from a germline VH chain. Evidence for evolutionary conserved self-binding locus. J Immunol (1990) 0.96
Review article: percutaneous endoscopic gastrostomy in infants and children. Aliment Pharmacol Ther (2010) 0.96
Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis. Eur J Clin Pharmacol (1985) 0.96
Anti-receptor antibody. I. Isolation and characterization of the immunoglobulin receptor for phosphorylcholine. J Immunol (1975) 0.96
Influence of ranitidine on plasma metoprolol and atenolol concentrations. Br Med J (Clin Res Ed) (1983) 0.95
Neonatal short bowel syndrome as a model of intestinal failure: physiological background for enteral feeding. Clin Nutr (2012) 0.94
Atenolol interaction with aspirin, allopurinol, and ampicillin. Clin Pharmacol Ther (1983) 0.94
Cerebral toxicity of penicillins in relation to their hydrophobic character. Naunyn Schmiedebergs Arch Pharmacol (1975) 0.94